Mohammad Amjad Kamal
King Abdulaziz University
Dr. Kamal is a Distinguish Adjunct Professor at King Fahd Medical Research Center (KFMRC), King Abdulaziz University, Jeddah, Saudi Arabia, where he was full Professor from March 2011 to March 2013. Prof. Kamal’s overall biochemical research output had culminated in more than 122 publications in internationally respected journals, and 61 abstracts in international conferences. His research was pivotal in supporting the development of the novel anti-Alzheimers agents from the laboratory to the clinic via collaboration with Dr Nigel H. Greig (Chief of Laboratory of Neurosciences in USA). He had migrated to Australia after an award of a prestigious U2000 Postdoctoral Fellowship in 2000 by the University of Sydney, School of Molecular and Microbial Biosciences. This three years highly competitive award funded his research on “Inhibition of amido phosphoribosyltransferase by new antifolates: Design and mechanism of action of purine antagonists". Prof. Kamal also collaborated in one of the molecular biological research project (Type 2 diabetic and Alzheimer’s disease) at the University of Technology Sydney. Recently his professional interest has taken a new turn as a Research Group Leader of Fundamental and Applied Biology Group as well as "Research Unit Coordinator" of "Metabolomics & Enzymology Unit". His group has been composed of several units in the cutting-edge field of medical sciences such as Metabolomics & Enzymology, Proteomics/Structural Biology, Tumor Biology, Recombinant DNA Technology. This research aims to focus on advancing the scientific research at KFMRC in providing health translational services to humanity particularly local Arab community. He is serving KFMRC Publication Committee (KPC) as a Coordinator and also selected as a scientific member of Chair "Yousef Abdul Latif Jameel Therapeutic Applications in the Prophets medicine". Moreover, he is acting as a guest editor of various journals such as special issues of the ‘CNS & Neurological Disorders-Drug Targets’, Current Drug Metabolism and ‘Evidence-Based Complementary and Alternative Medicine’.
Neurodegenerative Disorders Development of the novel anti-Alzheimer's agents